title: Therapeutic benefits of budesonide in gastroenterology.
abstract: Budesonide is a synthetic steroid of the glucocorticoid family with a high topical anti-inflammatory activity. Enteric-coated formulations resist gastric-acid degradation, delivering active drug to the small intestine and proximal colon. Budesonide has a high first-pass metabolism with minimal systemic absorption. It is therefore felt to cause fewer side effects than traditional glucocorticosteroids and to be generally well tolerated. The aim of this paper is to examine the utility of this medication in frequently encountered gastrointestinal conditions: Crohn's disease, ulcerative colitis, microscopic colitis and eosinophilic oesophagitis. A Medline search was performed to find published original research and review articles relating to the use budesonide in common gastroenterological conditions. The results showed that budesonide is efficacious in the induction and short-term maintenance of Crohn's disease. Budesonide is the best-documented treatment for microscopic colitis. It is well proven to be effective in the induction of remission in collagenous colitis but its use in lymphocytic colitis remains less well documented. In conclusion, budesonide is an effective glucocorticosteroid therapy for many chronic gastrointestinal diseases. In combination with its efficacy, the low incidence of serious side effects associated with this drug should keep it at the forefront in the therapeutic arsenal of any gastroenterologist.
authors.affiliation: Colm A. O'Morain, DSc (University of London), DSc Honoris Causa (University of Athens), MSc, MD, MA, Dip. Imm., FACG, FEBG, FRCP, FRCPI, FTCD, AGAF, Consultant Gastroenterologist, Professor of Medicine, Dean of Health Sciences Department of Gastroenterology, AMNCH/Trinity College Dublin, Dublin, Ireland.
authors.forename: Sarah
authors.initials: S
authors.lastname: O'Donnell
authors.forename: Colm A
authors.initials: CA
authors.lastname: O'Morain